| 3703 | ESC Guidelines for the management of cardiovascular diseases during pregnancy | New aspects in the pregnancy guidelines. | V.Regitz-Zagrosek ( Berlin-Germany) | Congenital heart disease / Pediatric cardiology | 30 Aug 2011 |
| 3704 | ESC Guidelines for the management of cardiovascular diseases during pregnancy | Identification and management of the high-risk patient. | J W.Roos-Hesselink ( Rotterdam-Netherlands) | Congenital heart disease / Pediatric cardiology | 30 Aug 2011 |
| 3705 | ESC Guidelines for the management of cardiovascular diseases during pregnancy | Which arrhythmias need treatment. | C.Blomstrom-Lundqvist ( Uppsala-Sweden) | Congenital heart disease / Pediatric cardiology | 30 Aug 2011 |
| 3706 | ESC Guidelines for the management of cardiovascular diseases during pregnancy | How to manage anticoagulation in pregnant women. | P G.Pieper ( Groningen-Netherlands) | Congenital heart disease / Pediatric cardiology | 30 Aug 2011 |
| 3749 | Can the polypill save the world? | Cardiovascular prevention; a global problem. | U.Keil ( Muenster-Germany) | Prevention and rehabilitation | 30 Aug 2011 |
| 3750 | Can the polypill save the world? | Polypill for primary prevention. | S.Yusuf ( Hamilton-Canada) | Prevention and rehabilitation | 30 Aug 2011 |
| 3751 | Can the polypill save the world? | Polypill for secondary prevention. | V.Fuster ( New York-United States of America) | Prevention and rehabilitation | 30 Aug 2011 |
| 3752 | Can the polypill save the world? | Alternatives to polypills. | AJ.Taylor ( Washington-United States of America) | Prevention and rehabilitation | 30 Aug 2011 |
| 3784 | Controversial issues on transcatheter aortic valve implantation | What are the current indications? | G C.Schuler ( Leipzig-Germany) | valvular disease | 30 Aug 2011 |
| 3785 | Controversial issues on transcatheter aortic valve implantation | Very high-risk patients with aortic stenosis: TAVI, balloon or nothing? | J.Rodes Cabau ( Sainte-Foy-Canada) | valvular disease | 30 Aug 2011 |
| 3787 | Controversial issues on transcatheter aortic valve implantation | Is valve-in-valve the preferred treatment for bioprosthesis failure? | D.Himbert ( Paris-France) | valvular disease | 30 Aug 2011 |
| 3794 | Primary percutaneous coronary intervention: from evidence to practice | Controversies in antithrombotic treatment. | A.Kastrati ( Munchen-Germany) | Ischaemia / ACS / infarction | 30 Aug 2011 |
| 3795 | Primary percutaneous coronary intervention: from evidence to practice | Drug-eluting or bare metal stents? | M.Valgimigli ( Ferrara-Italy) | Ischaemia / ACS / infarction | 30 Aug 2011 |
| 3796 | Primary percutaneous coronary intervention: from evidence to practice | The challenge of multi-vessel disease. | C.Di Mario ( London-United Kingdom) | Ischaemia / ACS / infarction | 30 Aug 2011 |
| 3797 | Primary percutaneous coronary intervention: from evidence to practice | Dealing with microvascular obstruction. | F.Crea ( Roma-Italy) | Ischaemia / ACS / infarction | 30 Aug 2011 |
| 3798 | New therapies for mitral regurgitation | Surgical strategies. | M.De Bonis ( Milano-Italy) | Interventional cardiology | 30 Aug 2011 |
| 3799 | New therapies for mitral regurgitation | Percutaneous edge to edge technique. | OW.Franzen ( Copenhagen-Denmark) | Interventional cardiology | 30 Aug 2011 |
| 3800 | New therapies for mitral regurgitation | Percutaneous coronary sinus annuloplasty. | J.Harnek ( Lund-Sweden) | Interventional cardiology | 30 Aug 2011 |
| 3801 | New therapies for mitral regurgitation | The bird's eye view. | A.Vahanian ( Paris-France) | Interventional cardiology | 30 Aug 2011 |
| 3883 | Joint Guidelines for the detection and treatment of dyslipidemias | Plasma lipids and global cardiovascular risk. | I M.Graham ( Dublin-Ireland) | Pharmacology and pharmacotherapy | 30 Aug 2011 |
| 3884 | Joint Guidelines for the detection and treatment of dyslipidemias | Controlled clinical trials and cardiovascular risk. | G.De Backer ( St Martens Latem-Belgium) | Pharmacology and pharmacotherapy | 30 Aug 2011 |
| 3885 | Joint Guidelines for the detection and treatment of dyslipidemias | The new joint Guidelines: an overview. | M-R.Taskinen ( Helsinki-Finland) | Pharmacology and pharmacotherapy | 30 Aug 2011 |
| 3886 | Joint Guidelines for the detection and treatment of dyslipidemias | New biomarkers for atherosclerosis. | O.Wiklund ( Goteborg-Sweden) | Pharmacology and pharmacotherapy | 30 Aug 2011 |
| 3909 | EURObservational Research Programme of the ESC. Ongoing Registries | EORP: what and why. | L.Tavazzi ( Cotignola-Italy) | | 30 Aug 2011 |
| 3910 | EURObservational Research Programme of the ESC. Ongoing Registries | General Registry: Heart Failure. | A P.Maggioni ( Florence-Italy) | heart failure / LV dysfunction | 30 Aug 2011 |
| 3911 | EURObservational Research Programme of the ESC. Ongoing Registries | Sentinel Registry: Ablation in Atrial Fibrillation. | J.Brugada Terradellas ( Barcelona-Spain) | Arrhythmias / Pacing / Resynchronisation | 30 Aug 2011 |
| 3912 | EURObservational Research Programme of the ESC. Ongoing Registries | Special Registry: Pregnancy in Cardiac Disease. | J W.Roos-Hesselink ( Rotterdam-Netherlands) | | 30 Aug 2011 |
| 3979 | Hot Line III - Acute coronary syndromes | PRODIGY: Randomized comparison of six versus twenty-four months clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all comer patients undergoing percutaneous coronary intervention. Results of the PRODIGY trial. | M.Valgimigli ( Ferrara-Italy) | Interventional cardiology | 30 Aug 2011 |
| 3980 | Hot Line III - Acute coronary syndromes | Discussant - PRODIGY: Randomized comparison of six versus twenty-four months clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all comer patients undergoing percutaneous coronary intervention. Results of the PRODIGY trial. | A.Kastrati ( Munchen-Germany) | Interventional cardiology | 30 Aug 2011 |
| 3981 | Hot Line III - Acute coronary syndromes | The RUBY-1 trial: safety, tolerability and efficacy of YM150, an oral factor Xa inhibitor, in secondary prevention of ischaemic vascular events in patients following a acute coronary syndrome | P G.Steg ( Paris Cedex 18-France) | Ischaemia / ACS / infarction | 30 Aug 2011 |
| 3982 | Hot Line III - Acute coronary syndromes | Discussant - The RUBY-1 trial: safety, tolerability and efficacy of YM150, an oral factor Xa inhibitor, in secondary prevention of ischaemic vascular events in patients following a acute coronary syndrome | S D.Kristensen ( Aarhus N-Denmark) | Ischaemia / ACS / infarction | 30 Aug 2011 |
| 3983 | Hot Line III - Acute coronary syndromes | EXAMINATION: A randomized comparison between everolimus-eluting stent and bare metal stent in patients with ST-segment elevation myocardial infarction: the EXAMINATION trial | M.Sabate Tenas ( Barcelona-Spain) | Interventional cardiology | 30 Aug 2011 |
| 3984 | Hot Line III - Acute coronary syndromes | Discussant - EXAMINATION: A randomized comparison between everolimus-eluting stent and bare metal stent in patients with ST-segment elevation myocardial infarction: the EXAMINATION trial | W.Wijns ( Aalst-Belgium) | Interventional cardiology | 30 Aug 2011 |
| 3985 | Hot Line III - Acute coronary syndromes | Newer generation everolimus-eluting stents eliminate the risk of very late stent thrombosis compared with early generation sirolimus-eluting and paclitaxel-eluting stents | L.Raber ( Bern-Switzerland) | Interventional cardiology | 30 Aug 2011 |
| 3986 | Hot Line III - Acute coronary syndromes | Discussant - Newer generation everolimus-eluting stents eliminate the risk of very late stent thrombosis compared with early generation sirolimus-eluting and paclitaxel-eluting stents | J.Fajadet ( Toulouse Cedex 3-France) | Interventional cardiology | 30 Aug 2011 |
| 3987 | Hot Line III - Acute coronary syndromes | CRISP AMI: A multi-center, randomized, controlled study of mechanical left ventricular unloading with Counterpulsation to Reduce Infarct size pre-PCI for Acute Myocardial Infarction: rationale and design of the CRISP AMI trial | M.Patel ( Durham-United States of America) | Ischaemia / ACS / infarction | 30 Aug 2011 |
| 3988 | Hot Line III - Acute coronary syndromes | Discussant - CRISP AMI: A multi-center, randomized, controlled study of mechanical left ventricular unloading with Counterpulsation to Reduce Infarct size pre-PCI for Acute Myocardial Infarction: rationale and design of the CRISP AMI trial | K.Huber ( Vienna-Austria) | Ischaemia / ACS / infarction | 30 Aug 2011 |